About
Jiangsu Hengrui Medicine Co Ltd (SHG:600276) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 22 2026
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
Mar 30 2026
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
Mar 26 2026
Hengrui Pharma Announces Strong 2025 Annual Results
Feb 10 2026
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide
Nov 4 2025
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
Financials
Revenue
CN¥31.63 B
Market Cap
CN¥375.34 B
P/E Ratio
47.78
EPS
1.18
Dividend Yield
0.35%